AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00125606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conditioning for allogeneic HSCT
Study NCT00756535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Group-based exercise training 5 days a week during hospitalization
Study NCT00756535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment and rehabilitation
Description: usual treatment and rehabilitation
Study NCT00920803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
Study NCT00920803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT501
Description: SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
Study NCT04305067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
Study NCT02771613 — intervention group
Intervention type: OTHER
Intervention: Multi professional in situ simulation
Description: After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
Study NCT02771613 — intervention group
Intervention type: OTHER
Intervention: Large diffusion of information
Description: After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
Study NCT00523445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline(Chantix)
Description: The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
Study NCT00523445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
Study NCT02237534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Study NCT00336479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study NCT02248597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT02248597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT02248597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT04577040 — intervention group
Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Drugs
Study NCT04462198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-505
Description: Intratympanic injection
Study NCT04462198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intratympanic injection
Study NCT00639080 — intervention group
Intervention type: OTHER
Intervention: Stop lipid lowering therapy (statin)
Description: Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
Study NCT02468336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioDefender
Study NCT02468336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT02262169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 2 Omeprazole capsules 20 mg, once daily
Study NCT02262169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo caplet of DLBS2411
Description: 1 placebo caplet of DLBS2411, twice daily
Study NCT02262169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS2411
Description: 1 DLBS2411 caplet 250 mg, twice daily
Study NCT02248597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo myeloablative or reduced intensity allogeneic stem cell transplant
Study NCT02237534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Study NCT03568188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment with focal HIFU
Description: HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
Study NCT03568188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
Study NCT03568188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.
Study NCT03568188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
Study NCT03568188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.
Study NCT03568188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
Study NCT03568188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine test
Description: if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
Study NCT02957214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain education
Description: The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
Study NCT02262169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule of Omeprazole
Description: 2 placebo capsules of Omeprazole, once daily
Study NCT01980485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lung Age feedback and exhaled carbon monoxide
Description: In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation.
Study NCT01980485 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Lung Age Feedback
Description: Those allocated to the control group will simply be informed of their scores on the spirometry.
Study NCT03425253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BELKYRA®
Description: BELKYRA® was injected into preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart).
Study NCT02248597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT03425253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA™ with Lidocaine
Description: Juvéderm® VOLUMA™ with Lidocaine VOLUMA™ was injected along the mandibular border.
Study NCT01430169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: Two injections of AA4500 0.58 mg 24 hours apart
Study NCT02874144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ compound
Description: 40 mg three times daily po for 12 weeks
Study NCT02874144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of Biological Specimens
Description: collection of biomarkers for analysis of nasal disease
Study NCT02874144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Collection of Biological Specimens
Description: collection of biomarkers for analysis of nasal disease
Study NCT02874144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid
Description: QD Nasal Spray
Study NCT02874144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal corticosteroid
Description: QD Nasal Spray
Study NCT02874144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
Study NCT05089851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
Study NCT05089851 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: Subjects will receive 20 - 24 units to the crows feet (10 - 12 units per side)
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Facial Cleanser to be used by participants twice daily
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial Cleanser
Description: Facial Cleanser to be used by participants twice daily
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by study participants after serum twice daily.
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by study participants after serum twice daily.
Study NCT02366000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Parental Training Intervention
Description: The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
Study NCT02366000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief Parental Training Intervention
Description: The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
Study NCT00773279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexTouch®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
Study NCT00773279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlexPen®
Description: All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
Study NCT03365778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Educational Intervention
Description: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
Study NCT03365778 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
Study NCT03365778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ophthalmologist Educational Intervention
Description: Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.
Study NCT01737931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical steroid (Dexamethasone)
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
Study NCT01737931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical antihistamine (Diphenhydramine)
Description: for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
Study NCT03983551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase 4 Inhibitor
Description: Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
Study NCT03983551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
Study NCT05089851 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Bland Sunscreen to be used by study participants after serum and moisturizer in the morning. Sunscreen to be reapplied if continuous sun exposure occurs.
Study NCT03919097 — intervention group
Intervention type: OTHER
Intervention: Medical Data extraction
Description: Data extraction from the patient's Medical Files
Study NCT02690571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
Study NCT02690571 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bronchoscopy
Description: The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
Study NCT02248597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT03432897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: 300 mg BID
Study NCT00834080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
Study NCT03432897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: 22-42 days post Olaparib patients will undergo surgery
Study NCT01058278 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Selective Laser trabeculoplasty
Description: The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
Study NCT01058278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser trabeculoplasty
Description: The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
Study NCT03718845 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mind-Body Medicine Curriculum
Description: The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
Study NCT01295060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: 84 mg Octreotide Implant
Study NCT03047265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
Study NCT03047265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
Study NCT04835246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra IMDx system
Description: The Spectra IMDx system is intended to be used in conjunction with conventional white light endoscopy in upper gastrointestinal endoscopic procedure to identify patients with high risk of developing and/or having gastric cancer and it is intended for use on patients above and equal to the age of 18.
Study NCT03749395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
Study NCT04948008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI306
Description: IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
Study NCT03183128 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated